Up | AC
Home Page
Food and
Drug Administration
Cardiovascular and Renal Drugs Advisory
Committee
October 16, 2007
Briefing Information
Regulatory considerations for extending
the use of phosphate binders to the pre-dialysis population.
Disclaimer
The statements contained in this document(s)
are those of the product's sponsor, not FDA, and FDA does not necessarily agree
with the sponsor's statements. FDA has not made a final determination about the
safety or effectiveness of the product described in this document.
GENZYME CORPORATION,
FRESENIUS MEDICAL CARE NORTH AMERICA AND SHIRE PHARMACEUTICALS
Briefing Document (pdf)
FDA
The FDA has no formal
briefing document for this Advisory Committee meeting